Peptides: The Science, Uses & Safety | Dr. Abud Bakri
This episode features Andrew Huberman and Dr. Abud Bakri, an internal medicine physician, in a masterclass discussion on peptides. They explore various categories of peptides, including FDA-approved GLP-1 agonists and non-FDA approved compounds like BPC-157, pinealon (EDR), GHK-Cu, and thymus peptides. The conversation delves into the science, mechanisms, safety profiles, anecdotal uses, and complex regulatory landscape surrounding these compounds, highlighting sourcing challenges and the ethical dilemmas clinicians face.
- BPC-157, a peptide touted for healing, has no identified specific receptor, meaning its core mechanism is still a scientific mystery. This isn't just a detail; it's a gaping hole in understanding how it truly works. Read →
- Beware Hidden Markups: Some doctors may prescribe GLP-1 agonists like Ozempic at $1,500/month, while a compounded version from another clinic could cost as little as $300. This disparity often hides clinician profit, making your choice an ethical and financial one. Read →
- Somatopause is real: Around your 30s, natural growth hormone (GH) production drops significantly, a phase called somatopause, impacting recovery and vitality. Read →
- Almost all active pharmaceutical ingredients (APIs) for peptides originate in China. There are no American-made peptides; they are only finished here, a fact Bakri confirmed directly. Read →
- The thymus, vital for immunity, shrivels post-puberty. Learn how peptides like Thymosin Alpha 1 offer a path to regenerate it and boost resilience. Read →